This Circle helps physicians capture and monetize real-world data from their everyday delivery of Shockwave for Shoulder Tendinopathy.

The Shockwave Market was valued at $1.34 Billion in 2023, and is estimated to grow to $2.4 Billion by 2030. Shoulder Tendinopathy is the most common diagnosed, accounting for 65%-70% of all shoulder pain presented in clinical settings. Shoulder Tendinopathy increases with age, due to the degeneration of tendons. With global life expectancy increasing, manufacturers will increase spending to obtain regulatory approvals for marketing shockwave products. Increasingly, that spend will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Shoulder Tendinopathy cases, outcomes and other case data.